Bristol-Myers Squibb (BMS) SWOT and PESTLE Analysis
COMPANY PROFILE -Bristol-Myers Squibb (BMS)
Business Sector :Pharmaceuticals
Operating Geography :United States, North America, Global
About Bristol-Myers Squibb (BMS) :
Bristol-Myers Squibb (BMS) is an American pharmaceutical company, headquartered in New York City. Their products are sold worldwide (U.S. being the biggest market, contributing 63% to overall revenue) and manufactured in the U.S., Puerto Rico and in five foreign countries. BMS was formed by the 1989 merger of Squibb (founded in 1858 in Brooklyn) and Bristol-Myers (founded in 1887 in Clinton, New York). Their Products can be categorized in the following major therapeutic classes: oncology; cardiovascular; immune-science; and virology, including HIV infection. As of 2021, it employees 32,200 people globally. Bristol Myers Squibb has been named a U.S. EPA Energy Star Partner of the Year (ESPOY) for the eighth consecutive year, receiving the Sustained Excellence designation for the past four years. A definitive merger agreement between Bristol Myers Squibb and Turning Point Therapeutics, Inc. was announced in March 2022. Bristol Myers Squibb will buy Turning Point Therapeutics for $76.00 per share. The deal is expected to be finalised in the third quarter of 2022. With the help of this deal, Bristol will be able to maximise the capabilities of its precision oncology platform and raise the bar for cancer patients' care.
The USP of Bristol lies is that it is one of the world’s largest pharmaceutical companies. Bristol mission statement states ‘To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.’ While vision is “To be the world's leading biopharma company that transforms patients' lives through science”.
Bristol-Myers Squibb (BMS) Revenue :
$46.4 billion – FY ending 31st Dec 2021 (y-o-y growth 9%)
$42.5 billion – FY ending 31st Dec 2020
Competitive Analysis of Bristol-Myers Squibb (BMS)
1. Innovation – New Product Development 2. Strong focus on Research and Development 3. Strong and diverse brand portfolio 4. High credit rating, low borrowing cost 5. Complimentary alliances for vertical integration 6. Breakthrough solutions developed for diseases | 1. Revenue dependence on few prioritized brands 2. Weak presence in biologics segment 3. Major dependency on US and European markets 4. Loss of market exclusivity of the products |
1. Growing cancer immunotherapy market 2. Increasing globalization in Pharma industry, opening of new markets through trade agreements 3. Leverage advance digital technologies to transform healthcare | 1. Increasing competition from generic drugs manufacturers 2. Changes in U.S. or foreign laws and regulations 3. Adverse changes in U.S., global, regional or local economic conditions |
Complete Report
USD 15.53
- Debit/Credit card
- PayPal

Detailed SWOT Analysis of Bristol-Myers Squibb (BMS)
Strength
1. Innovation – new product development: Bristol-Myers Squibb is known for its innovative capabilities to discover, develop and deliver transformational medicines. They have achieved significant research breakthroughs in therapeutic areas such as Oncology, Immuno-science, Cardiovascular and Fibrosis. Bristol Myers Squibb continued to introduce new medicines, including Breyanzi for large B-cell lymphoma and Abecma for multiple myeloma, making it the first company to have two cell therapy treatments approved for two different targets. During the course of the year, they also reached significant clinical and regulatory milestones across its portfolio, expanding the potential of Zeposia® and introducing it as the first oral treatment for ulcerative colitis.
2. Strong focus on Research and Development: BMS has maintained its status as one of the most innovative pharma companies by investing heavily on R&D. R&D expenses were $11.4 billion in 2021, $11.1 billion in 2020 and $6.1 billion in 2019, showing a strong trend. In 2020, Bristol expanded its location in Lawrenceville, New Jersey, and it will construct a new R&D facility in Cambridge, Massachusetts (planned for 2023). Additionally, they are enhancing their manufacturing capabilities by erecting brand-new cutting-edge cell therapy manufacturing facilities in Devens, Massachusetts, and Leiden, the Netherlands, in support of their ongoing investment in their cell therapy portfolio. BMS employed approximately 8,400 people in R&D and related support activities, including a substantial number of physicians, scientists holding graduate or postgraduate degrees and higher-skilled technical personnel.
The remaining section under "Strength" is available only in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
Complete Report
USD 15.53
- Debit/Credit card
- PayPal

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?



You may also be interested in other analyses of Bristol-Myers Squibb (BMS):
-
Bristol-Myers Squibb (BMS) Porter's Five Forces Analysis -
Bristol-Myers Squibb (BMS) VRIO Analysis -
Bristol-Myers Squibb (BMS) Value Chain Analysis -
Bristol-Myers Squibb (BMS) Covid-19 Impact Analysis -
Bristol-Myers Squibb (BMS) BCG Analysis -
Bristol-Myers Squibb (BMS) Segmentation, Targeting and Positioning (STP) Analysis -
Bristol-Myers Squibb (BMS) Ansoff Matrix Analysis


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Check Out Analysis of Other Relevant Companies
References used in Bristol-Myers Squibb (BMS) SWOT & PESTLE Analysis Report
1. Annual Report - https://annual-report.bms.com/assets/bms-ar/documents/2021-annual-report.pdf
2. Bristol Myers Squibb - https://en.wikipedia.org/wiki/Bristol_Myers_Squibb
3. Newsroom - https://news.bms.com/news/default.aspx
4. Awards and Achievement - https://www.bms.com/about-us/our-company/achievements.html
5. U.S. FDA approves new Bristol Myers cancer immunotherapy - https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-new-bristol-myers-cancer-immunotherapy-2022-03-18/
The detailed complete set of references are available on request in the 'Complete report' on purchase.
How to Reference This Page?
You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.
Bristol-Myers Squibb (BMS) SWOT and PESTLE Analysis - SWOT & PESTLE.COM
SWOT & PESTLE.com (2023). Bristol-Myers Squibb (BMS) SWOT and PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/bristol-myers-squibb/ [Accessed 29 Nov, 2023].
In-text: (SWOT & PESTLE.com, 2023)
Copyrights and Disclaimer
Bristol-Myers Squibb (BMS) SWOT and PESTLE analysis has been conducted by Sachin Mishra and reviewed by senior analysts from Barakaat Consulting.
Copyright of Bristol-Myers Squibb (BMS) SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.